Back to Results
First PageMeta Content
Selective serotonin reuptake inhibitors / Organofluorides / Abnormal psychology / Eli Lilly and Company / Antidepressant / Paroxetine / Fluoxetine / Management of depression / Major depressive disorder / Chemistry / Organic chemistry / Psychiatry


Document Date: 2006-12-12 09:10:03

Open Document

File Size: 1,97 MB

Share Result on Facebook

City

Cassell / Tindall / Bellevue / England /

Company

Lilly / M.D. / /

Country

United States / Netherlands / United Kingdom / /

Facility

Northwest Clinical Research Center / Arch Gen Psychiatry / /

IndustryTerm

treatment for depression / pharmaceutical / energy / /

MedicalCondition

major depressive disorder / episode depression / adult depression / anxiety disorders / serious disorder / MS / depression / /

MedicalTreatment

drug therapy / /

Organization

Harvard Medical School / Northwest Clinical Research Center / Psychopharmacologic Drugs Advisory Committee / MHRA / FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE / FDA / Medicines Evaluation Board / DEPARTMENT OF HEALTH AND HUMAN SERVICES / /

Person

Martin Teicher / Lisa Jones / Mark Levenson / Marc Stone / Jitschak Storosum / Thomas P. Laughren / Chris Holland / Arif Khan / /

Position

psychiatrist / Director / Division of Psychiatry Products HFD-130 SUBJECT / physician / events representative / representative / General / PM MEDICAL OFFICER / /

Product

fluoxetine / Prozac / /

ProvinceOrState

Washington / /

Technology

drug development / /

URL

http /

SocialTag